Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellmunt, Joaquim, Lalani, Aly-Khan A., Jacobus, Sussana, Wankowicz, Stephanie A., Polacek, Laura, Takeda, David Y., Harshman, Lauren C., Wagle, Nikhil, Moreno, Irene, Lundgren, Kevin, Bossé, Dominick, Van Allen, Eliezer M., Choueiri, Toni K., Rosenberg, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173710/
https://www.ncbi.nlm.nih.gov/pubmed/30220708
http://dx.doi.org/10.1038/s41416-018-0261-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173710/
https://www.ncbi.nlm.nih.gov/pubmed/30220708
http://dx.doi.org/10.1038/s41416-018-0261-0

Ejemplares similares